Researchers engineered nanovesicles from senescent tumor cells (nano-APMs) that accumulate in the spleen and prime CD8+ T cells to specifically target radiation-resistant cancer cells. When combined with radiotherapy, these nano-APMs mobilized T cells to eliminate senescent tumor cells and reprogram the immunosuppressive tumor environment in mouse models. This approach represents a sophisticated solution to a critical cancer therapy limitation. Radiotherapy often creates senescent tumor cells that become highly resistant to treatment and actively suppress immune responses, leading to treatment failure and recurrence. Current senolytic drugs lack specificity and cause significant toxicity. The nano-APM strategy cleverly exploits the enhanced antigen-presenting capacity of senescent cells, turning their resistance mechanism into a vulnerability. By priming the immune system in advance, then triggering localized senescence with radiation, this creates a spatiotemporally coordinated attack on the most problematic cancer cells. While promising, the work remains in preclinical mouse models, and translating nanovesicle-based immunotherapies to humans faces significant manufacturing and delivery challenges. The concept of immunological memory against therapy-resistant cancer cells could reshape how we sequence cancer treatments.